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Summary
Background Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET 
mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data 
are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the 
phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. 
Methods This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET 
variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients 
followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to 
determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had 
undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, 
incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. 
Findings 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort 
died at a median age of 25 years (range <1–59). Thyroidectomy was done before the age of 1 year in 20 patients, which 
led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes 
unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any 
significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves 
by log-rank test: p=0∙2; hazard ratio 0⋅35; 95% CI 0.07–1.74). However, there was a significant difference in remission 
status between patients who underwent thyroidectomy before and after the age of 1 year (p<0∙0001). There was a 
significant difference in remission status between patients who underwent thyroidectomy before and after the age of 
1 year (p<0∙0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and 
structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 
(50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients 
had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available 
data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body 
habitus, mucosal neuromas, and gastrointestinal signs. 
Interpretation Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality 
is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing 
surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To 
improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine 
signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of 
the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.
Funding None. 
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Multiple endocrine neoplasia type 2B is a rare genetic 
syndrome (prevalence, 0⋅9–1⋅6 per million individuals) 
caused by germline mutations in the proto-oncogene 
RET.1,2 The syndrome is most commonly caused by the 
Met918Thr RET mutation (>95% cases) followed by the 
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Ala883Phe RET mutation (<5% cases);3,4 very rarely, 
the disease results from tandem RET mutations.5
Precise data for the phenotypic characteristics and 
natural history of patients carrying the most common 
Met918Thr mutation remain scarce. Multiple endo-
crine neo plasia type 2B can include medullary thyroid 
carcinoma, phaeochromocytoma, and extra-endocrine fea-
tures. Prognosis is hampered by the syndrome’s main 
clinical feature, medullary thyroid carcinoma. Multiple 
endocrine neoplasia type 2B that is associated with med-
ullary thyroid carcinoma is observed worldwide, often 
clinically aggressive, and of early onset.6 It is preceded by a 
C-cell hyperplasia and can evolve quickly to lymph node 
invasion and systemic disease through vascular invasion.6,7
The largest study to date of 75 patients concluded that 
the prognosis has improved over the past 20 years 
because of earlier management of medullary thyroid 
carci noma.8 Three previous studies, based on 
18–44 patients, gave insight into the natural history of the 
disease and became the basis for the guidelines on the 
management of the disease.9–12 These studies showed that 
the prognosis of medullary thyroid carcinoma in multiple 
endocrine neo plasia type 2B depends on the stage at 
diagnosis and that only early diagnosis and intervention 
provided a chance for cure. Brauckhoff and co-workers11 
emphasised the need for awareness of the extra-
endocrine signs, given the fact that medullary thyroid 
carcinoma would be only palpable on clinical examination 
far later than the age recommended of younger than 
1 year for thyroidectomy,11,13 and the majority of multiple 
endocrine neoplasia type 2B cases arise because of 
de novo RET mutations.10
Research in context
Evidence before this study
Multiple endocrine neoplasia type 2B is a rare genetic syndrome 
that arises from an activating mutation (primarily the 
Met918Thr variant) in the rearranged during transfection (RET) 
proto-oncogene. Given the rarity of the syndrome, published 
data are scarce and are primarily limited to a few referral 
centres. Medullary thyroid cancer is the predominant finding in 
multiple endocrine neoplasia type 2B, developing within the 
first year of life and leading to early death due to metastatic 
medullary thyroid carcinoma in most cases. It is currently 
recommended that thyroidectomy be done before the age of 
1 year to prevent the early metastatic spread of medullary 
thyroid carcinoma, yet this recommendation is not 
evidence-based and is rarely done because most multiple 
endocrine neoplasia type 2B cases arise de novo and the 
diagnosis is not made until long after the onset of metastatic 
and incurable medullary thyroid carcinoma. The second major 
component of multiple endocrine neoplasia type 2B is 
phaeochromocytoma, for which the first-line treatment is 
adrenalectomy. Historically, the treatment has been total 
adrenalectomy, although surgical advances have led to the 
broader use of adrenal-sparing procedures, which have not 
been studied in multiple endocrine neoplasia type 2B 
specifically. Finally, multiple endocrine neoplasia type 2B is also 
associated with extra-endocrine features, such as alacrima and 
symptoms of gastrointestinal dysmotility, which can present 
during infancy, thus allowing the astute clinician who 
recognises this association to make the correct diagnosis early 
enough to prevent the onset of metastatic medullary thyroid 
carcinoma through early thyroidectomy.
Added value of this study
345 patients from 48 centres across the world were included in 
the largest study on multiple endocrine neoplasia type 2B ever 
published, to our knowledge. We report for the first time an 
extensive description of the phenotype and natural history of 
multiple endocrine neoplasia type 2B. This study emphasises 
the benefits of early thyroidectomy before the age of 1 year, 
as it led to a long-term cure in 15 (83%) of 18 patients who 
were operated on. Surprisingly, at a median age of 25 years, 
47 (15%) patients operated on later than 1 year were still cured, 
while 64 (20%) of our patients had died, highlighting the 
phenotypic heterogeneity of the syndrome. All patients had at 
least one extra-endocrine feature, and more than half of them 
had the classic association of marfanoid body habitus, 
gastrointestinal signs, and mucosal neuromas—clinical signs 
that should warn health providers of a potential diagnosis of 
multiple endocrine neoplasia type 2B. Half of the patients had 
bilateral phaeochromocytomas by the age of 28 years and, 
for the first time, the benefits of adrenal-sparing surgery are 
reported, which resulted in normal adrenocortical function in 
62% of patients and was associated with a low risk of 
recurrence. Finally, we report for the first time, to our 
knowledge, the social consequences of the syndrome, as a 
quarter of our patients were disabled due to its clinical features.
Implications of all the available evidence
Multiple endocrine neoplasia type 2B is an orphan disease 
associated with a substantially altered quality of life and poor 
survival primarily due to metastatic medullary thyroid 
carcinoma. Means to improve the prognosis of patients with 
multiple endocrine neoplasia type 2B include making the 
diagnosis earlier and better understanding the natural history 
and management of disease features. The evidence has clearly 
shown that the clinical presentation of the syndrome begins at 
birth, and improved education of all health providers about the 
extra-endocrine signs should lead to earlier diagnosis and 
improved outcomes through earlier thyroidectomy. Improving 
the functional prognosis can also be achieved through 
appropriate management of phaeochromocytoma via 
adrenal-sparing surgery, which should lead to less adrenal 
insufficiency and the need to take life-long adrenal replacement 
therapy. Future studies should focus on the factors explaining 
the phenotypic variations in terms of disease aggressiveness.
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Therefore, all health-care providers treating children 
should be aware of the various extra-endocrine clinical 
signs4,14,15 that should raise concern for multiple endocrine 
neoplasia type 2B in the differential diagnosis. This 
earlier identification would help patients benefit from 
early thyroidectomy to avoid metastatic disease.12 The 
second principal feature of multiple endocrine neoplasia 
type 2B is phaeochromocytoma, but few data about this 
feature of the disease are avail able. The two largest series 
reported 26 and 15 patients with multiple endocrine 
neoplasia type 2B and phaeo chromocytoma.8,16 The 
penetrance of phaeo chromocytoma is lower than that of 
medullary thyroid carcinoma.16
Given the sparsity of published data, and taking 
advantage of a large international tertiary referral centre 
network, we sought to provide more insight into the 
natural history of multiple endocrine neoplasia type 2B. 
Our main aim was to improve understanding of the 
phenotype and natural history of the condition, on the 
basis of current guidelines, which in turn would lead to 
improved awareness of this complex syndrome and the 
extra-endocrine signs to allow for optimal detection and 
essential and functional prognosis of these predominantly 
young patients.
Methods
Study design and participants
This international study was initiated on April 1, 2016. 
Experts from centres all over the world (appendix) 
founded a consortium to include all their available 
retrospective data in a registry to analyse in detail the 
diagnosis, management, and outcomes of patients with 
multiple endocrine neoplasia type 2B.
Patients included in the database had to be diagnosed 
as carriers of a germline pathogenic Met918Thr RET 
mutation. There were no age restrictions and no other 
inclusion criteria were used. Additionally, first-degree 
relatives with histo logically proven medullary thyroid 
carcinoma and patients presenting with the association 
of medullary thyroid carcinoma, phaeochromocytoma, 
and extra-endocrine signs suggestive of multiple 
endocrine neoplasia type 2B (at a time when genetic 
testing was not available) were included. Some of these 
patients had been previously reported with incomplete 
data. For such patients, updated and exhaustive data 
were re-extracted from their updated medical records 
(appendix).2,9,17–19 Patients who were carriers of a germline 
pathogenic RET Ala883Phe mutation were not included 
because of a recent report on the natural history of such 
patients.20 This work conforms to the Declaration of 
Helsinki, Good Clinical Practice guidelines, and was 
approved by the appropriate local institutional review 
boards or ethics committees. All patients gave signed 
informed consent for genetic DNA analysis. For the 
retrospective analysis of existing data sets from routine 
patient care, the majority of the centres did not require 
additional specific institutional review board approval. 
Some centres had ethics committee approval or 
institutional review board authorisation for the use of 
anonymised data without additional patient consent 
(Belgium, Canada, China, Czech Republic, Denmark, 
France, Hungary, Japan, Netherlands, and Poland). Some 
centres had an additional consent form signed by the 
patients (Argentina, Chile, Spain, and UK). National 
Institutes of Health patients included in this study were 
enrolled in a National Cancer Institute, Pediatric 
Oncology Branch medullary thyroid cancer natural 
history study (NCT01660984).
Procedures
We included retrospective, routinely collected data about 
medullary thyroid carcinoma, phaeochromocytoma, 
extra-endocrine features with no age restrictions, and 
schooling and professional attainment (in patients older 
than 10 years). The following data were collected 
regarding medullary thyroid carcinoma: age at diagnosis 
and first surgery, sex, type of surgery, pTNM classification, 
calci tonin level before and after surgery, treatments 
received, and final outcome (disease status and final vital 
status, including cause of death). The following data 
were collected regarding phaeochromocytoma: age at 
diagnosis and type of surgery (adrenal-sparing vs total 
adrenal ectomy), pathological diagnosis, recurrence, post-
surgical adrenal insufficiency, and final outcome. Data 
from patients followed up from Jan 1, 1970 to April 1, 2016 
were retrieved from May 1, 2016 to May 31, 2018. The 
principal investigator (FC) collected the data, which were 
provided by each centre. A potential confounder was the 
risk of incomplete data in the medical files of each 
patient. To minimise the effect of this unavoidable 
confounder, for extra-endocrine features, the presence or 
absence of a specific sign was recorded only when it was 
specifically noted as present or absent in the medical 
records. 
Outcomes
Our primary objective was to analyse the overall survival 
and medullary thyroid carcinoma-specific survival in 
patients with multiple endocrine neoplasia type 2B 
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Figure 1: Overall survival based on age at last follow-up (Kaplan-Meier 
estimates)
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based on whether they had undergone early 
thyroidectomy at the age of 1 year or less, as 
recommended by international guidelines.12 Our 
secondary objectives were specifically to better 
characterise the natural history of medullary thyroid 
carcinoma and phaeochromocytoma and to establish the 
penetrance of extra-endocrine features. For medullary 
thyroid carcinoma, final disease status was defined as 
follows: remission by normal calcitonin and 
carcinoembryonic antigen levels and no residual disease 
on imaging; biochemical persistence by increased 
calcitonin or carcinoembryonic antigen, or both, with no 
residual disease on imaging; biochemical and cervical 
persistence by increased calcitonin or carcinoembryonic 
antigen, or both, with pathological cervical lymph nodes; 
biochemical and systemic persistence by increased 
calcitonin or carcinoembryonic antigen, or both, with 
systemic metastases on imaging. Follow-up imaging 
modalities were selected by each investigator. For phaeo-
chromocytoma, the size of the tumour was defined by 
the pathological analysis when available, or initial 
imaging in other cases. Phaeo chromocytoma was 
determined to be malignant by the presence of 
metastases to lymph nodes or other tissues (eg, lungs, 
bones, or liver). We also compared disease-free survival 
after adrenal-sparing surgery or adrenalectomy in 
patients with phaeochromocytoma, and examined 
adrenal function recovery after adrenal-sparing surgery. 
Data for extra-adrenal tum ours (eg, para ganglioma) 
were also collected. Finally, data were also gathered 
about the extra-endocrine fea tures of multiple endocrine 
neoplasia type 2B, and any other diseases the patients 
might have presented with during their follow-up. The 
presence or absence of a specific extra-endocrine feature 
was noted only when it was specifically reported in the 
data file of the patients. Suggestions of a particular 
feature were not counted unless the file explicitly said it 
was present.
Statistical analysis
We summarised continuous variables as mean and SD 
or median (range), or both. We did statistical com-
parisons of quantitative data with Student’s t test or 
ANOVA. For statistical comparisons of dichotomous 
data, we used the χ² test with Yates’ correction. We 
established over all survival and medullary cancer-
specific survival and compared patients with thyroid-
ectomy before or after 1 year of age with log-rank 
analysis. We calculated age-dependent penetrance 
estimates of phaeochromocytoma with the Kaplan-Meier 
method. All statistical tests were two-sided, and p values 
of less than 0∙05 were considered statistically significant. 
All analyses were done with Prism (version 6) for 
MacOs X.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
48 centres were part of the consortium. 20 patients were 
excluded because of incomplete data. 345 patients 
(184 women, 161 men) were included. Among them, 
276 (84%) of 330 with available data on familial status 
were de novo cases (non-familial). 115 patients had been 
All patients 
operated on 
(n=338)
Patients 
operated on at 
1 year old or 
younger (n=20)
Patients 
operated on at 
older than 1 year 
old (n=318)
p values
Age at thyroidectomy (IQR) 14 years (17) 9 months (6) 14 years (18∙5) <0∙0001
Calcitonin (fold upper limit of 
normal; IQR)
180∙3 (1145∙1) 6∙2 (11∙4) 182∙0 (1082∙2) <0∙0001
Pathology <0∙0001 
Normal 2 (0∙5%) 2 (10%) 0
C-cell hyperplasia without 
medullary thyroid 
carcinoma
9 (2∙6%) 3 (15%) 6 (2%)
Medullary thyroid 
carcinoma
327 (97%) 15 (83%) 312 (98%)
Medullary thyroid carcinoma 
size (mm, IQR)
21 (27) 4 (3) 23 (24) <0∙0001
Medullary thyroid carcinoma 
size <10 mm
51 (15%) 14 (70%) 37 (12%)
Systematic lymph node 
dissection
241/312 (77%) 14/19 (74%) 227/293 (77%) 0∙24
Normal calcitonin after 
surgery
57/223 (26%) 15/20 (83%) 43/206 (21%) <0∙0001
Age at last follow-up, years 
(IQR)
25 (17) 6 (11) 26 (17) <0∙0001
Final outcome <0∙0001 
Remission 62 (18%) 15/18* (83%) 47 (15%)
Biochemical persistence 58 (17%) 0 58 (18%)
Biochemical and cervical 
persistence
47 (14%) 2 (10%) 45 (14%)
Biochemical and systemic 
persistence
105 (31%) 1 (5%) 104 (33%)
Deaths 66 (20%) 2 (10%) 64 (20%)
Medullary thyroid 
carcinoma
43 (65%) 0 43 (67%)
Phaeochromocytoma 2 (3%) 0 2 (3%)
Gastrointestinal 
complications of multiple 
endocrine neoplasia 
type 2B
2 (3%) 1 (50%) 1 (2%)
Unknown reasons 19 (44%) 1 (50%) 18 (28%)
Data are n (%), n/N (%), or median (IQR) unless specified. p values compare thyroidectomy before and after 1 year. 
Remission was defined by normal calcitonin and carcinoembryonic antigen levels and no residual disease on imaging; 
biochemical persistence by increased calcitonin or carcinoembryonic antigen, or both, with no residual disease on 
imaging; biochemical and cervical persistence by increased calcitonin or carcinoembryonic antigen, or both, with 
pathological cervical lymph nodes; biochemical and systemic persistence by increased calcitonin or carcinoembryonic 
antigen, or both, with systemic metastases on imaging. *2 patients died of causes unrelated to medullary thyroid 
carcinoma.
Table 1: Multiple endocrine neoplasia type 2B-related medullary thyroid carcinoma with thyroid surgery
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previously reported in six different studies, with 
incomplete data (appendix p 4). At a median age of 
25 years (range <1–66, IQR 17) at last follow-up, 71 
(21%) patients had died. Median age at death was 25 years 
(range <1–59). 209 (92%) of 227 patients were alive by age 
20, 37 (65%) of 57 by age 40, and 5 (42%) of 12 by age 60. 
Overall survival is shown in figure 1. 
338 (98%) of 345 patients had a thyroid ectomy. 
Seven (2%) patients did not have a thyroidectomy: 
six patients because of metastatic and progressive dis-
ease at the time of diagnosis (median age 27 years; 
range 21–32, IQR 6), and one because of fatal com-
plications of intestinal ganglio neuromatosis at the age of 
6 months. At a median age at thyroidectomy of 14 years 
(range 3 months–47 years, IQR 17), medullary thyroid 
carcinoma was found in 327 (97%) of 338 patients. It was 
limited to the thyroid in only 53 (17%) of 312 patients for 
whom lymph node dissection was done. 43 (14%) of 
338 patients died due to metastatic medullary thyroid 
carcinoma (with metastasis in one or more sites: liver 
[28], lungs [26], bone [17] and/or brain [8]) at a median 
age of 25 years (range 6–59, IQR 16; table 1).
Medullary thyroid carcinoma-specific survival curves 
did not show any significant difference between patients 
who had early or delayed thyroid ectomy (figure 2; 
comparison of survival curves by log-rank test: p=0⋅2; 
hazard ratio 0⋅35; 95% CI 0⋅07–1⋅74). By contrast, there 
was a significant difference in remission status between 
patients operated before and after the age of 1 year 
(p<0∙0001; table 1).
As shown in the appendix, 20 patients had a thyroid-
ectomy at no later than 1 year of age (median 9 months, 
range 3–12, IQR 0∙5) as identified based on their medical 
records. During follow-up, two patients had died (neither 
from medullary thyroid carcinoma): one at the age of 
6 months because of complications of intestinal ganglio-
neuromatosis and the other at the age of 3 years with no 
cause of death specified. At last follow-up, at a median of 
5∙2 years after thyroidectomy (range 3 months–32∙0 years, 
IQR 10∙6), 15 (83%) of 18 surviving patients who 
underwent thyroidectomy at the age of 1 year or less were 
in biochemical and struct ural remission, while three (17%) 
of 18 individuals had persistent biochemical and structural 
disease. 
In the group of 318 patients who had a thyroidectomy 
after 1 year of age, 64 (20%) patients were deceased, 
including 43 due to medullary thyroid carcinoma, at a 
median age of 25 years (range 8–59, IQR 18∙5). At last 
follow-up, at a median of 13 years after thyroidectomy 
(range 1⋅7–25∙0, IQR 13∙9), 47 (15%) patients were in 
biochemical and structural remission, while 207 (65%) 
had persistent disease, including 104 (33%) who pro-
gressed to systemic metastases requiring chemot herapy 
(n=8), oral targeted therapy (n=34), or liver-directed 
radiofrequency ablation (n=2; data not shown). Data were 
not available for the remaining 59 patients. T and N status 
Number of patients
Patients with phaeochromocytoma 153/313 (49%)
Median age at first diagnosis of 
phaeochromocytoma (years [IQR])
24 (9)
Symptomatic at first diagnosis 71/127 (56%)
Diagnosis
Before medullary thyroid carcinoma 8/137 (6%; delay of 
3 years, IQR 2)
At the same time as medullary thyroid 
carcinoma
35/137 (26%)
After medullary thyroid carcinoma 94/137 (69%; delay of 
8 years, IQR 8)
Unilateral phaeochromocytoma at last 
follow-up
42/153 (27%)
Bilateral phaeochromocytoma at last follow-up 111/153 (73%)
Synchronous bilateral phaeochromocytoma 79/153 (52%)
Asynchronous bilateral phaeochromocytoma 32/153 (21%)
Patients with adrenal surgery 146/153 (95%)
Unilateral 51 (35%)
Bilateral 95 (65%)
Patients with adrenalectomy 115/153 (79%)
Recurrence 11 (10%)
Adrenal insufficiency 69* (100%)
Patients with at least one adrenal-sparing 
surgery
31/153 (20%)
Right adrenal 13 (42%) 
Left adrenal 11 (36%) 
Both sides 7 (23%) 
Recurrence 3 (10%)
Adrenal insufficiency 10† (38%)
Metastatic phaeochromocytoma 4/153 (3%)
Median age at last follow-up (years [IQR]) 25 (8)
Death due to phaeochromocytoma 2/153 (<1%)
Data are n (%) or n/N (%) unless specified. *69 patients underwent bilateral 
adrenalectomy. †A total of 26 patients underwent bilateral adrenal surgery and at 
least one adrenal-sparing surgery. 
Table 2: Phaeochromocytoma
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Figure 2: Kaplan-Meier estimates of medullary thyroid carcinoma-specific 
survival in patients who underwent early (≤1 year old) versus late (>1 year 
old) thyroidectomy 
HR=hazard ratio.
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at diagnosis is shown in the appendix. Of note, nine (56%) 
of 16 patients operated between the ages of 1 year and 4 
years had persistent disease at last follow-up (data not 
shown).
Clinical data regarding phaeochromocytoma were 
available for 313 patients. A diagnosis of at least 
one phaeochromocytoma was made in 153 (49%) of 
313 patients at a median age of 24 years (range 13–52, IQR 9; 
table 2). 146 (95%) patients had undergone surgery as 
treatment for phaeochromocytoma at last follow-up. 
Bilateral synchronous phaeochromocytoma was the initial 
diagnosis in 79 (52%) patients. The median size of the 
larger phaeochromocytoma was 30 mm in diameter 
(range 6–175, IQR 31) whereas the contralateral one was 
19 mm (range 3–75, IQR 17). Among the 74 remaining 
patients (48%) with a first diagnosis of unilateral phaeo-
chromo cytoma, 32 patients developed a metachronous 
con tralateral phaeochromocytoma at a median of 4 years 
(range 2–16, IQR 3∙2) after the first phaeochromocytoma 
diagnosis (table 2). Penetrance of unilateral phaeochromo-
cytoma was 50% by the age of 25 years, whereas penetrance 
of bilateral phaeochromocytoma was 50% by the age of 
28 years (figure 3).
Comparing adrenal sparing and total adrenalectomy in 
patients with multiple endocrine neoplasia type 2B and 
pheochromocytoma, 31 (20%) of 153 patients had at least 
one adrenal-sparing surgery. In all patients who 
underwent surgery, 14 (10%) of 146 patients developed 
recurrence at a median age of 34 years (range 24–54, 
IQR 10∙8), including three patients who had undergone 
adrenal-sparing surgery and 11 who had an adrenalectomy 
(p=0⋅56; data not shown). For the three patients, 
recurrence had been diagnosed at 5 years in one 
individual and 6 years in the other two, after the organ-
sparing surgery. Among the 26 patients with bilateral 
adrenal surgery and at least one adrenal-sparing surgery, 
normal adrenocortical function was observed in 16 (62%) 
patients (vs 0% in the adrenalectomy group; p<0∙0001; 
table 2). Four patients (3%) had metastatic phaeo-
chromocytoma at last follow-up, as evidenced by 
metanephrines hyper secretion, at a median age of 
41 years (range 35–45, IQR 5). Two patients had bilateral 
synchronous phaeo chromo cytoma at 27 and 40 years old, 
and two patients had metachronous phaeochromocytoma 
at the age of 19 and 23 years for the first patient, and 
25 and 29 years for the second patient.
The prevalence of extra-endocrine features is reported in 
table 3. All patients with available data (n=287) had at least 
one extra-endocrine feature. The association of marfanoid 
body habitus, ganglioneuromatosis, and gastrointestinal 
signs was reported in 106 (56%) of 190 patients for 
whom the presence or absence of these features was 
clearly noted in their medical records. Surgical intervention 
for extra-endocrine features was necessary in 28 patients 
(19 gastrointestinal surgeries including ten cases for 
symptomatic megacolon and nine with achalasia requiring 
oesophageal dilatation; five hip surgeries; and four bladder, 
prostate, or ureteral surgeries). Additional extra-endocrine 
features, probably not linked to multiple endocrine 
neoplasia type 2B, included seizures in four patients 
(without brain metastases), micrognathia in four cases, 
and congenital cataract in two cases (data not shown).
School and professional data from patients aged more 
than 10 years were available for 129 patients (median age 
31 years, range 10–66, IQR 17): 32 (25%) patients were 
unable to work or attend school because of disability at 
last follow-up (data not shown). 
Discussion
This international, retrospective study provides a de tailed 
description of the natural history and outcomes of 
Met918Thr RET multiple endocrine neoplasia type 2B. 
It emphasises the need for early thyroidectomy to 
improve survival, and the possibility of adrenal-sparing 
surgery to improve the functional outcome of patients 
with Met918Thr RET multiple endocrine neoplasia 
Number (%)
Ganglioneuromatosis 258/266 (97%)
Tongue 165/266 (62%)
Lips 142/266 (53%)
Eyelid or conjunctival 51/266 (19%)
Marfanoid habitus 193/266 (73%)
Pseudo Hirschsprung’s disease or severe constipation 168/257 (65%)
Achalasia or gastroparesis 9/257 (4%)
Pes cavus 63/166 (38%)
Pectus excavatum 45/172 (26%)
Motor or muscle weakness (hypotonia) 51/190 (27%)
Scoliosis 18/190 (9%)
Corneal hypertrophy 82/182 (45%)
Alacrima 66/167 (40%)
Kidney anomalies (eg, kidney atrophy, kidney cysts, 
hydronephrosis, and ureteral atonia)
25/189 (13%)
Data are n (%) of N. Note that the penetrance was based on the presence or absence 
of each feature specifically noted in the medical files of each patient. When no 
mention of the feature was noted, the information was considered as not available. 
Table 3: Extra-endocrine features
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Figure 3: Kaplan-Meier estimates of unilateral and bilateral 
phaeochromocytoma penetrance
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type 2B. It also highlights the need for an optimal extra-
endocrine management of these patients, because a 
quarter of them could be unable to work or attend school 
because of endocrine and extra-endocrine related dis-
ability, a point that has not been raised previously, to our 
knowledge, in studies mainly focusing on the out come of 
medullary thyroid carcinoma. These results should thus 
modify patient care and help establish future guidelines.
The importance of early diagnosis is shown by the 
medullary thyroid carcinoma outcome of patients who 
underwent thyroidectomy. Although only 15% of patients 
were cured when thyroidectomy was done after the age of 
1 year, 83% were cured when thyroidectomy was done 
before or at the age of 1 year (p<0∙0001; table 1). This 
finding shows the need for early thyroidectomy—ie, before 
the age of 1 year. Although there had been suggestions to 
postpone thyroidectomy to the age of 4 years,10 our study 
calls for caution as nine (56%) of our 16 patients operated 
between the ages of 1 year and 4 years had persistent 
disease at last follow-up (data not shown). Although our 
study did not collect data for surgical complications, the 
high rate of cure of medullary thyroid carcinoma with early 
thyroidectomy could outweigh the associated risks, such as 
laryngeal nerve injury or hypopara thyroidism, even though 
these can substantially affect an infant’s life. To mini-
mise risks, surgeries in patients with multiple endocrine 
neoplasia type 2B should only be done by experienced, 
high-volume thyroid cancer surgeons. However, the 
possibility of early thyroidectomy is hampered by the 
difficulty in making an early diagnosis.11,13 Indeed, 
the diagnosis of multiple endocrine neoplasia type 2B 
remains a challenge because of the high proportion of de 
novo mutations and the absence of endocrine symptoms 
at an early age. In a series of 44 patients, Brauckhoff and 
colleagues10 reported that the chance of remission was 
higher in patients who had been diagnosed based on 
recognition of extra-endocrine features of multiple 
endocrine neoplasia type 2B (ie, by a non-endocrinologist). 
Although marfanoid body habitus and mucosal neuro mas 
typically appear after the age of 1 year, features such as 
constipation, pseudo-obstruction, or feeding difficult ies 
are early signs that should lead to further evaluation for the 
syndrome. Gastrointestinal signs were present in two-
thirds of our patients and Brauckhoff and co-workers11 
reported tear production abnormalities (alacrima) as an 
additional early sign of multiple endocrine neoplasia 
type 2B. Proper education of paediatricians, ophthal-
mologists, dentists, gastroenterol ogists, orthopaedic sur-
geons, and general practitioners is thus crucial, as they 
represent the front line for early diagnosis. Notably, we 
also found a surprisingly large number of patients (n=47, 
15%) who underwent thyroidectomy after the age of 1 year 
who were in biochemical and structural remission at last 
follow-up. These results also emphasise the heterogeneity 
and phenotypic variability of multiple endocrine neoplasia 
type 2B, as all but one of these 47 patients required only a 
single delayed surgery to achieve remission.
In this study, the penetrance of phaeochromocytoma 
was high: 50% of all patients developed a phaeochromo-
cytoma and 50% of these were bilateral by 28 years of age. 
As a comparison, we had previously reported that 20% of 
patients with the RET 634 codon mutation and 5% with 
RET exon 10 mutations had bilateral phaeochromo-
cytoma by 28 years of age.18 Makri and colleagues19 
reported in a study of eight patients with multiple 
endocrine neo plasia type 2B-associated phaeochromo-
cytoma a 10-year-old patient with an asymptomatic 
phaeochromocytoma. This identification of phaeochro-
mo cytoma in a 10-year-old is in line with international 
guidelines, which recom mend a first biological screening 
at 11 years of age in Met918Thr multiple endocrine 
neoplasia type 2B. Overall, consider ing synchronous 
or metachronous appearance, phaeochromocytoma was 
bilateral in most of our patients (73%). This observation 
highlights the need to consider adrenal-sparing surgery 
in these patients, who would otherwise be at risk for life-
long adrenal insufficiency. As 61% of patients who 
underwent adrenal-sparing surgery had normal 
adrenocortical function, the results seem similar to those 
reported for multiple endocrine neoplasia type 2A.18 
The rate of malignant phaeochromocytoma was similar 
to reported numbers for other RET mutations,18 and 
two patients of 66 died of phaeochromo cytoma or 
consequences of catecholamine hypersecretion.
Our study has inherent limitations due to its retro-
spective nature. However, multiple endocrine neoplasia 
type 2B is a very rare syndrome and the most suitable 
approach to improve its understanding was to 
retrospectively analyse the data from a large number of 
centres. This study design results in incomplete data 
(especially for the earlier signs that allowed diagnosis, 
the age at which these signs were first seen by the 
physician, or the presence or absence of extra-endocrine 
features in patients diagnosed during adulthood; some 
precise pathological characteristics such as TNM status 
for phaeochromocytoma or extent of lymph node 
resection), subjective data extraction, and heterogeneous 
follow-up. We collected the data of only 20 patients with 
thyroid ectomy before the age of 1 year. This low number, 
associated with a short follow-up, probably explains why 
we did not find any significant difference between 
patients operated before and after the age of 1 year, but 
there was a significant difference in remission status. 
This finding should not modify the aggressive early 
management of such patients, as shown in table 1.
In summary, the different clinical courses and out-
comes of medullary thyroid carcinoma and phaeo-
chromo cytoma, in addition to the varying penetrance of 
extra-endocrine features, make multiple endocrine neo-
plasia type 2B a complex syndrome characterised by wide 
phenotypic variability despite being a defined single gene 
disorder. Our data underscore the importance of pur-
suing thyroidectomy before 1 year of age, which requires 
an early non-endocrine diagnosis; highlight the value of 
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doing adrenal-sparing surgery in patients with phaeo-
chromocytoma when technically feasible; and emphasise 
the need for a multidisciplinary approach lifelong to the 
treatment of both the endocrine and extra-endocrine 
features, which should be systematically reported in 
medical files whether present or not. Additionally, our 
data highlight that a large proportion of these young 
patients become disabled. One of our future aims will be 
to show whether the natural history of patients with 
multiple endocrine neoplasia type 2B can be modified by 
novel drugs or techniques. Therefore, our study improves 
understanding regarding the long-term outcomes of 
multiple endocrine neoplasia type 2B, but more work 
remains to be done to obtain a global understanding of 
this rare syndrome. 
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